



Published in final edited form as:

Oncogene. 2010 January 14; 29(2): 201–213. doi:10.1038/onc.2009.323.

Notch-1 activates estrogen receptor- α -dependent transcription via IKK α in breast cancer cells

L Hao¹, P Rizzo¹, C Osipo¹, A Pannuti², D Wyatt¹, LW-K Cheung^{1,3}, G Sonenshein⁴, BA Osborne⁵, and L Miele²

¹Breast Cancer Program, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA

²University of Mississippi Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA

³Department of Preventive Medicine and Bioinformatics Core, Loyola University Chicago, Maywood, IL, USA

⁴Department of Biochemistry, Boston University, Boston, MA, USA

⁵Department of Veterinary and Animal Sciences, University of Massachusetts at Amherst, Amherst, MA, USA

Abstract

Approximately 80% of breast cancers express the estrogen receptor- α (ER α) and are treated with anti-estrogens. Resistance to these agents is a major cause of mortality. We have shown that estrogen inhibits Notch, whereas anti-estrogens or estrogen withdrawal activate Notch signaling. Combined inhibition of Notch and estrogen signaling has synergistic effects in ER α -positive breast cancer models. However, the mechanisms whereby Notch-1 promotes the growth of ER α -positive breast cancer cells are unknown. Here, we demonstrate that Notch-1 increases the transcription of ER α -responsive genes in the presence or absence of estrogen via a novel chromatin crosstalk mechanism. Our data support a model in which Notch-1 can activate the transcription of ER α -target genes via IKK α -dependent cooperative chromatin recruitment of Notch–CSL–MAML1 transcriptional complexes (NTC) and ER α , which promotes the recruitment of p300. CSL binding elements frequently occur in close proximity to estrogen-responsive elements (EREs) in the human and mouse genomes. Our observations suggest that a hitherto unknown Notch-1/ER α chromatin crosstalk mediates Notch signaling effects in ER α -positive breast cancer cells and contributes to regulate the transcriptional functions of ER α itself.

Correspondence: L Miele, Ergon Professor of Medicine and Pharmacology, Director, University of Mississippi Cancer Institute, University of Mississippi Medical Center, 2500 N. State Street, Guyton 2, Building, Suite G751-05, Jackson, MS 39216, USA. lmiele@ci.umsmed.edu.

Conflicts of interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on the *Oncogene* website (<http://www.nature.com/onc>)

Keywords

breast cancer; estrogen; ER α ; IKK α ; Notch-1

Introduction

The Notch pathway regulates cell fate specification, differentiation, proliferation and apoptosis (Artavanis-Tsakonas *et al.*, 1999). Notch activates the expression of target genes via CSL factors (Artavanis-Tsakonas *et al.*, 1999; Nickoloff *et al.*, 2003; Miele, 2006). Notch targets include members of the HES (Artavanis-Tsakonas *et al.*, 1999), HERP (Iso *et al.*, 2001) and HEY (Maier and Gessler, 2000) families, p21^{Cip/Waf} (Rangarajan *et al.*, 2001), c-Myc (Klinakis *et al.*, 2006; Weng *et al.*, 2006), nuclear factor- κ B subunits (Cheng *et al.*, 2001), cyclin-D1 (Ronchini and Capobianco, 2001) and cyclin-A (Baonza and Freeman, 2005). Mammals have four Notch paralogs (Notch-1 through Notch-4) and five Notch ligands (delta-1, 3, 4 and Jagged-1 and 2). Notch also binds non-CSL transcription factors such as HIF-1 α (hypoxia-inducible factor-1 α ; Gustafsson *et al.*, 2005) and β -catenin (Hayward *et al.*, 2005), as well as Nur77, a nuclear-receptor-superfamily protein (Jehn *et al.*, 1999).

Recent data indicate that Notch signaling is critical in mammary development (Dontu *et al.*, 2004) and in mammary stem cell function and luminal fate commitment (Bouras *et al.*, 2008). Emerging evidence indicates that Notch signaling is frequently activated in breast cancer (Stylianou *et al.*, 2006). Notch activity has been suggested to correlate with proliferation, antiapoptosis and tumor progression in breast cancer (Miele, 2008). High expression of Notch-1 and Jagged-1 is associated with poor prognosis (Reedijk *et al.*, 2005, 2008; Dickson *et al.*, 2007). Constitutively active Notch-1 or Notch-4 cause mammary tumors in mice (Gallahan *et al.*, 1996; Gallahan and Callahan, 1997; Callahan and Raafat, 2001; Callahan and Egan, 2004; Kiaris *et al.*, 2004).

17 β -Estradiol (henceforth, E₂) promotes the growth of estrogen receptor- α (ER α)-positive breast cancer cells. Canonical ER α -responsive genes contain estrogen-responsive elements (EREs; Green and Carroll, 2007), whereas other genes recruit ER α through transcription factors such as AP1 or SP1 (Porter *et al.*, 1997; Jakacka *et al.*, 2001). Numerous protein complexes participate in ER α -mediated gene regulation (Green and Carroll, 2007). The best known ER coactivators are p160 family members, including steroid receptor coactivator-1 (SRC-1), AIB1/SRC-3 and SRC-2/TIF2/GRIP1. p160 proteins can recruit other coactivators such as CBP, p300 and P/CAF, which possess histone acetyltransferase activity (Perissi and Rosenfeld, 2005; Green and Carroll, 2007). The phosphorylation status of ER α regulates its activity (Cenni and Picard, 1999). ER α can be phosphorylated at multiple serine residues by various kinases, including IKK α (Park *et al.*, 2005), mitogen-activated protein kinases (Kato *et al.*, 1995; Bunone *et al.*, 1996) and Akt (Martin *et al.*, 2000; Campbell *et al.*, 2001). IKK α -kinase activity is required for E₂-mediated ER α phosphorylation and activation of downstream gene expression (Park *et al.*, 2005).

In addition to E₂, multiple growth factors such as insulin, IGF-1 and EGF can activate ER α through mitogen-activated protein kinases (Kato *et al.*, 1995; Bunone *et al.*, 1996); cyclin-

D1, which is frequently overexpressed or amplified in breast cancer, can bind ER α , recruit SRC-family coactivators and activate downstream gene expression in the absence of E₂ (Neuman *et al.*, 1997; Zwijnen *et al.*, 1997).

We have recently shown that in ER α -positive breast cancer cells E₂ inhibits Notch signaling by modulating Notch activation (Rizzo *et al.*, 2008). Conversely, E₂ deprivation or treatment with 4-hydroxytamoxifen re-activates Notch signaling and increases dependence on it for survival. Notch-1 knockdown causes growth arrest in T47D and MCF-7 cells, and potentiates the effects of 4-hydroxytamoxifen. Treatment of T47D xenografts with a combination of tamoxifen and a pharmacological Notch inhibitor (γ -secretase inhibitor (GSI)) caused tumor regression. These observations posed a fundamental question: Does Notch regulate a subset of ER α -target genes?

Results

Active Notch-1 facilitates transcription of ER α -target genes in the absence of E₂

We hypothesized that Notch activation in the absence of E₂ may rescue the expression of some critical E₂-target genes. Two well-known E₂-target genes, c-Myc and cyclin-D1, are also potential Notch targets in the mammary gland (Kiaris *et al.*, 2004; Klinakis *et al.*, 2006). Exploratory reverse transcription-PCR (RT-PCR) array studies indicated that expression of Notch-1IC (NIC) in MCF-7 cells in charcoal-stripped (E₂-deficient) medium transactivated a number of E₂-target genes (data not shown). Validation experiments by real-time RT-PCR confirmed that E₂-target genes vascular endothelial growth factor- α (VEGF α), CD44, cyclin-D1, c-Myc and pS2, and Notch-target gene HEY1, but not β -tubulin, are upregulated by NIC in charcoal-stripped medium (Figure 1a). We confirmed that E₂ induces the expression of VEGF α , CD44, cyclin-D1, c-Myc and pS2 in the cells used in this study (Supplementary Figure 1).

We then activated endogenous Notch by co-culturing MCF-7 cells in charcoal-stripped medium with mouse LTK fibroblasts engineered to express Notch ligand Jagged-1 (LTK-JAG1) or control vector-transduced parental fibroblasts (LTK-PAR). After 12 h of co-culture, mRNA levels of all tested E₂ targets were significantly upregulated by Jagged-1-expressing fibroblasts as compared with that by control fibroblasts (Figure 1b), whereas β -tubulin was not affected. Since Jagged-1 could potentially activate all four Notch receptors, we used a specific Notch-1 short interfering RNA (siRNA) and determined that Notch-1 knockdown prevented Jagged-1-expressing fibroblasts from activating pS2 transcription, whereas Notch-2 or Notch-4 siRNA did not affect the stimulation of pS2 expression by Jagged-1 (Supplementary Figure 2).

Next, we investigated the mechanism of Notch-mediated induction of these E₂-target genes. Sequence analysis revealed putative CSL-binding sites in proximity of ER α -binding elements in these promoters. These elements included canonical EREs, and in the case of cyclin-D1, an AP1 consensus sequence known to mediate ER α recruitment (Shen *et al.*, 2008). The c-Myc promoter contains an Sp1 site and an ERE half-site (Dubik and Shiu, 1992) within 2 kb of the transcriptional start (Figures 1c – g). We hypothesized that Notch-1 may be co-recruited with ER α . We performed a series of chromatin immunoprecipitation

(ChIP) experiments to detect Notch-1 and ER α at each of those promoters under different conditions. First, we confirmed E₂-dependent recruitment of ER α to those promoters after short-term E₂ treatment (Figures 1c–g, left). Interestingly, E₂ also caused significant recruitment of Notch-1 to the cyclin-D1 promoter, but not any other promoters that we analysed. This may suggest that Notch-1 participates in the transcriptional regulation of a subset of E₂-target genes in the presence of E₂. When we activated Notch in charcoal-stripped medium by co-culturing MCF-7 cells with Jagged-1-expressing mouse fibroblasts, Jagged-1 caused significant increases in promoter occupancy of both Notch-1 and ER α on all the promoters studied (Figures 1c–g, right). The induction was comparable to the increase of Notch-1 on the HEY1 promoter. Interestingly, ER α does not bind to the VEGF α promoter unless Notch is activated (Figure 1c). These observations supported the hypothesis that Notch can activate a subset of ER α -target genes under E₂-free conditions, and that Notch-1 is co-recruited to these promoters with ER α .

Notch activation increases ER-dependent transcription

In order to further investigate the molecular mechanism(s) whereby Notch activates ER-dependent transcription, we chose a well-characterized experimental model. The gene for TFF1/pS2 is an extensively studied model of transcriptional regulation by E₂. Its promoter contains a perfect half-ERE at position –263, which is used by ER α (Jeltsch *et al.*, 1987) as well as other regulatory elements within a relatively short DNA sequence (Nunez *et al.*, 1989; Gillesby *et al.*, 1997). We detected a putative CSL-binding site at position –240. Real-time RT–PCR experiments showed that pS2 mRNA level was increased by E₂ as expected. This effect was abrogated by fulvestrant, which causes ER degradation (Figure 2a). NIC expression in charcoal-stripped medium also significantly stimulated pS2 expression (Figure 2b). In the presence of E₂, NIC did not cause any additional stimulation over that achieved by E₂. Fulvestrant abolished NIC-mediated stimulation of pS2 expression, suggesting that ER is required for this Notch effect (Figure 2b). Conversely, neither E₂ nor fulvestrant affected NIC-induced HEY1 expression (Supplementary Figure 3).

We conducted similar experiments, this time activating Notch by co-culture with Jagged-1-expressing mouse fibroblasts. The results were essentially identical. Jagged-1 stimulation increased pS2 expression in charcoal-stripped medium, but did not further enhance the effects of E₂. Fulvestrant abolished the effects of Jagged-1 (Figure 2c). ER α levels were verified by western blotting (Figure 2d). Control experiments (Supplementary Figure 3) showed that expression of HEY1 mRNA was increased by Jagged-1-expressing cells. Consistent with our published observations (Rizzo *et al.*, 2008), E₂ inhibited HEY1 induction by Jagged-1 and fulvestrant restored it. We then explored the role of Notch-1 in basal pS2 expression. A specific siRNA to Notch-1 was used to knock down Notch-1 expression by approximately 70% (Figure 2e). Expression of pS2, but not β -tubulin, was dramatically decreased by Notch-1 siRNA in charcoal-stripped medium (Figure 2f). Similarly, a GSI inhibited pS2 expression in a dose-dependent manner (Figure 2g). The IC₅₀ for this effect was virtually identical to that for HEY1 inhibition (not shown). These experiments support the hypothesis that Notch-1 regulates pS2 expression in the absence of E₂, and basal pS2 expression under E₂-free conditions is Notch-1-dependent.

We investigated the mechanism of this effect by ChIP. Co-culture of MCF-7 cells with Jagged-1-expressing fibroblasts in charcoal-stripped medium caused recruitment of both Notch-1 (Figure 2h) and ER α (Figure 2i) to the pS2 promoter. Short-term E₂ treatment reduced the amount of Jagged-1-induced Notch-1 recruitment (Figure 2h), while increasing ER α as compared with that in the control. Fulvestrant nearly abolished the recruitment of Notch-1 and ER α to the pS2 promoter. We confirmed these results by knocking down ER α via siRNA (Figure 2j) before co-culture. In control cells transfected with scrambled siRNA, Jagged-1 co-culture caused dramatic upregulation of Notch-1 on the pS2 promoter in charcoal-stripped medium, which was significantly inhibited by E₂. In cells transfected with ER α siRNA, Jagged-1 did not increase the binding of Notch-1 or ER α on the same promoter in the presence or absence of E₂ (Figure 2k). These data support a model in which Jagged-1 causes co-recruitment of Notch-1 and ER α to the pS2 promoter, inducing gene expression. Notch-1 recruitment requires ER α even in charcoal-stripped medium, suggesting that unliganded ER α and Notch-1 cooperate in inducing pS2 expression. The inhibition of Notch recruitment by E₂ is consistent with our previous data (Rizzo *et al.*, 2008) and suggests a feedback mechanism.

IKK α and its kinase activity are required by Notch-1 for transcriptional activation of ER-dependent genes

We have shown that active Notch-1 associates with IKK α , promoting its recruitment to nuclear factor- κ B-dependent promoters (Song *et al.*, 2008). IKK α has numerous nuclear functions (Perkins, 2007), and was described as a necessary component of ER α -dependent transcriptional complexes in the presence of E₂ (Park *et al.*, 2005). Thus, we investigated whether Notch-1 may stimulate ER α -dependent transcription by facilitating the association of IKK α with ER α in the absence of E₂. First, we used a specific siRNA to IKK α . IKK α knockdown significantly decreased pS2 mRNA in charcoal-stripped medium (Figures 3a and b), indicating that MCF-7 cells require not only Notch-1 but also IKK α for basal pS2 expression in the absence of E₂. To determine whether IKK α is required for Notch-mediated activation of ER-dependent transcription, we expressed NIC in the absence of IKK α (Figure 3c). IKK α knockdown abolished the induction of pS2, but not HEY1, by NIC (Figure 3d), suggesting that IKK α is important for Notch-mediated activation of pS2 expression, but not for canonical Notch signaling in these cells. To rule out possible siRNA artifacts, we also used a dominant-negative (DN) form of IKK α (AA) in which two crucial catalytic residues are replaced by alanine (Arsura *et al.*, 2003). We coexpressed DN-IKK α with NIC in MCF-7 cells in charcoal-stripped medium (Figure 3e), and obtained similar results as with IKK α siRNA: DN-IKK α prevented NIC from activating pS2 but not HEY1 transcription (Figure 3f). Real-time RT-PCR data were complemented by ChIP experiments in which we activated Notch in MCF-7 cells by co-culture with Jagged-1-expressing fibroblasts in charcoalstripped medium, and measured Notch-1 or ER α occupancy of the pS2 promoter. While Jagged-1 stimulated the binding of Notch-1 and ER α to the promoter, either IKK α siRNA (Figure 3g) or DN-IKK α (Figure 3h) completely abolished this effect. Additionally, Jagged-1 co-culture increased the binding of IKK α to the pS2 promoter in the absence of E₂ (Figure 3i). Taken together, these data support a model in which Jagged-1 stimulates the recruitment of Notch-1, IKK α and ER α to the pS2 promoter. IKK α and its kinase activity are required for Jagged-1-induced promoter recruitment and pS2 transcriptional activation.

SRC-1 and SRC-3 are not required, but CSL and MAML1 are indispensable for the effect of Notch-1 on the pS2 promoter

Coactivators SRC-1 and/or SRC-3/AIB1 play an important role in ligand-dependent or independent ER α activation. These coactivators possess histone acetyltransferase activity and recruit additional histone acetyltransferases, such as p300 (Green and Carroll, 2007). ER α phosphorylation at S118, S167 and other residues increases its affinity for SRC-3 (Likhite *et al.*, 2006). IKK α is one of the kinases that can phosphorylate ER α S118. Thus, we asked whether Notch-1 can induce the recruitment of SRC-1 or SRC-3 to the pS2 promoter in the absence of E₂ via IKK α . Tamoxifen and its active metabolite 4-hydroxytamoxifen can prevent coactivator recruitment by ER α . CHIP assays showed that E₂, but not Jagged-1-mediated Notch activation, stimulated SRC-1 and SRC-3 binding to the pS2 promoter (Figures 4a and b). Thus, these canonical ER α coactivators are dispensable for Notch-1-mediated ER α activation. Consistent with this model, 4-hydroxytamoxifen did not affect pS2 or HEY1 induction by NIC, whereas fulvestrant did (Supplementary Figure 4).

Next, we asked whether canonical Notch partners, CSL and MAML1, are involved in this novel transactivation complex. We downregulated CSL by specific siRNA in charcoal-stripped medium (Figure 4c) and found that induction of HEY1 (Figure 4d) or pS2 (Figure 4e) by Jagged-1 was abolished. Similar results were obtained when we overexpressed a DN form of MAML1 (DN-MAML1), which binds to Notch-1 and CSL but lacks the domain responsible for coactivator recruitment (Weng *et al.*, 2003). In the presence of DN-MAML1, neither transient transfection of NIC (Figure 4f), nor Jagged-1 co-culture (Figure 4g), could activate HEY1 or pS2 expression. CHIP data indicated that CSL and MAML1, but not SRC1, are recruited to the pS2 promoter when Notch is activated in the absence of E₂ (Figure 4h).

The Notch-1 and ER α transcriptional complexes interact in chromatin-enriched nuclear extracts, leading to MAML-1-dependent p300 recruitment

Based on our CHIP results showing that Notch-1 binds to the pS2 promoter in an ER-dependent manner, we hypothesized that the Notch-1 and ER α transcriptional complexes may physically interact on the chromatin. We took two different IP strategies to test this hypothesis. First, we used a quantitative co-IP assay using a chimeric construct comprised of full-length Notch-1 fused at the C-terminus with *Renilla* luciferase (N1-RL) (Vooijs *et al.*, 2004; Figure 5a). We immunoprecipitated cytoplasmic extracts and chromatin-enriched nuclear extracts from cells transfected with N1-RL, with an ER α -specific antibody or nonspecific IgG. We determined the fraction of luciferase activity immunoprecipitated by anti-ER α as compared with that by nonspecific IgG. We could specifically co-precipitate N1-RL and ER α in chromatin-enriched nuclear lysates but not in cytoplasmic lysates. N1-RL could also be co-immunoprecipitated with known Notch-binding partners CSL and MAML1, which were used as positive controls (Figure 5c). Negative controls, glyceraldehyde-3-phosphate dehydrogenase-RL (GAPDH-RL) and Cdc2-RL, could not be co-immunoprecipitated with ER α . Similar results were observed in reverse IP experiments where we transfected cells with an ER α -RL construct and immunoprecipitated luciferase activity with either Notch-1 or CSL antibodies (Figure 5d).

We confirmed the interaction between ER α and the Notch-1/CSL transcriptional complex by traditional IP–western blot from chromatin-enriched nuclear extracts. Figure 5e shows that Notch-1 and ER α can be co-immunoprecipitated only in nuclear extracts, and CSL is part of the complex. To verify the identity of the Notch-1 band, we used two Notch-1 antibodies to detect the interaction between Notch-1 and ER α : we immunoprecipitated with a polyclonal C-terminal antibody, C-20, or ER α , and detected western blots with either C-20 or a specific antibody to NIC, which recognizes the N-terminal epitope generated by γ -secretase cleavage. We confirmed that the Notch-1 band we co-immunoprecipitate with ER α is NIC. This interaction appeared to be DNA-dependent, since it was abolished by pretreatment of nuclear lysates with the DNA intercalator ethidium bromide before IP (Supplementary Figure 5). These data indicate that the Notch-1 and ER α transcriptional complexes are in close proximity to each other and may form a large DNA-bound supramolecular complex. Additionally, IKK α and MAML1 could be detected in association with ER α only when Notch-1 was present (Figure 5f). Notch-1 knockdown abolished complex formation, and completely prevented the nuclear translocation of IKK α . Interestingly, after Notch-1 knockdown IKK α was found in association with ER α in the cytoplasm but not in the nucleus, indicating that Notch may affect the nuclear localization of ER α in the absence of E₂. To test this hypothesis, we transfected the MCF-7 cells with the ER–RL construct, and measured luciferase activity in cytoplasmic or nuclear fractions after co-culturing MCF-7 cells with Jagged-1-expressing fibroblasts. We observed significant shift of luciferase activity from the cytoplasm to the nucleus in MCF-7 cells co-cultured with Jagged-1-expressing fibroblasts, which do not express ER α . Western blots on the same lysates confirmed this observation (Supplementary Figure 6). These data support a model in which Notch-1 is required for chromatin recruitment of IKK α , as we showed in a different model (Song *et al.*, 2008), and can trigger nuclear migration of ER α in the absence of estrogen.

Notch activation induces recruitment of p300 to the pS2 promoter

p300/CBP functions as a coactivator for ER α (Green and Carroll, 2007) and Notch/CSL (Miele, 2006). SRC–p300 complexes are essential for transcriptional initiation on ER-dependent promoters (Green and Carroll, 2007). Thus, we explored p300 recruitment to the pS2 promoter upon Notch activation. CHIP experiments showed similar levels of p300 on the pS2 promoter when cells were treated with E₂ or co-cultured with Jagged-1-expressing fibroblasts after 3 days of hormone deprivation (Figures 6a and b). p300 recruitment was abolished by IKK α siRNA (Figure 6c). Notch-1 and ER α could be co-immunoprecipitated with p300. This interaction was inhibited by IKK α knockdown (Figure 6d). MAML1 recruits p300 to the CSL–Notch transcriptional complex (Saint Just *et al.*, 2007). When we transfected MCF-7 cells with DN-MAML1, the interaction between ER α and p300 was inhibited (Figure 6e). These data support a model in which in the absence of E₂ MAML1 rather than p160-family coactivators is responsible for Notch-1-induced p300 recruitment to ER α -dependent promoters.

Discussion

We describe a novel crosstalk between Notch-1 and ER α , whereby Notch-1 transactivates a subset of ER α -responsive genes via a mechanism that requires IKK α and MAML1, but not

SRC1 or SRC3. The working model supported by our data is shown in Figure 7. The transcriptional effects of Notch activation are notoriously context-dependent. Part of this context dependence may result from a complex interplay between the Notch transcriptional complex (NTC) and other cell type-specific transcription factors. Evidence (Nam *et al.*, 2007) supports a model in which two DNA-bound NTCs bind cooperatively to some Notch-responsive genes. Our data suggest that the NTC is also capable of forming complexes with ER α . Thus, in breast cancer cells, the effects of Notch activation would depend on ER α expression and E₂ concentration.

Estrogen receptor- α can regulate transcription positively and negatively, and it can bind DNA directly via EREs or other transcription factors such as AP1 or SP1 (Carroll *et al.*, 2006). Pioneer factors such as FoxA1 play a key role in recruiting ER α to specific DNA sites upon E₂ treatment (Laganier *et al.*, 2005). ER α -binding DNA sites can be found as far as 50–100 kb from regulated genes (Lin *et al.*, 2007). Several sites can cooperate in the regulation of individual genes (Eeckhoutte *et al.*, 2006). A widely accepted model of E₂ regulation of cyclin-D1 suggests that recruitment of FoxA1 to a downstream enhancer facilitates E₂-activated binding of ER α to this site and additional upstream sites (Laganier *et al.*, 2005). Among these, an AP1 site at –934 recruits ER α and p300. This site is contained in the amplicon that we analysed (P2 site in Figure 1f), as is a putative ERE. A bioinformatic scan of the human and mouse genomes revealed that canonical EREs are found at specific spacing distances from CSL-responsive elements with highly statistically significant frequencies (Supplementary Figure 7). Many of these sequence pairs are found within 2 kb of genes conserved between humans and mice (not shown). Genome-wide studies will be necessary to determine which of these genes are co-regulated by Notch-1 and ER α , which subset of the known ER α binding sites is close to CSL responsive elements, whether Notch-1 influences DNA site usage by ER α , and whether AP1-tethered or SP1-tethered ER α also cooperate with Notch-1. This is possible, based on our data on the cyclin-D1 and c-Myc promoters. Notch-1 is recruited both by E₂ and by Jagged-1 to a region in the cyclin-D1 promoter known to bind ER α via AP1 (Shen *et al.*, 2008). The SP1 site in the c-Myc promoter thought to be important in mediating E₂ transcriptional effects is very close to our amplicon (Dubik and Shiu, 1992). We focused on a relatively small and well-characterized promoter, pS2, whose active regulatory elements are found in the vicinity of the transcriptional start.

Our data demonstrate a key role for nuclear IKK α in Notch-1-ER α cooperation. IKK α stimulates ER α activity in the presence of E₂ (Park *et al.*, 2005), by phosphorylating ER α and/or histone H3, and is necessary for transcriptional induction of cyclin-D1 by mitogenic signals (Albanese *et al.*, 2003). We have previously shown that in CaSki cervical cancer cells, Notch-1 associates with IKK α and is required for its recruitment to the c-IAP2 promoter (Song *et al.*, 2008). This study indicates that IKK α is found in association with ER α and MAML1 in the nucleus only in the presence of Notch-1. Taken together, these findings suggest that promoting the chromatin recruitment of IKK α is a novel function of Notch-1, through which Notch-1 can mediate crosstalk with other transcription factors. IKK α has been suggested to regulate Notch signaling via phosphorylation of nuclear I κ B α in 3T3 cells (Aguilera *et al.*, 2004). Abnormal IKK α activity in colon cancer cells was reported to increase Notch transcriptional activity (Fernandez-Majada *et al.*, 2007). Our data from

CaSki cells (Song *et al.*, 2008) are consistent with that model. However, in MCF-7 cells, IKK α was not required for Notch-mediated induction of HEY1, whereas being absolutely required for crosstalk with ER α . It is likely that the accessory role of IKK α in Notch signaling depends on cell type and target genes.

A physical association between Notch-1 and a nuclear receptor, Nur77, was shown in 1999 in T-cells (Jehn *et al.*, 1999). In our model, the interaction between the Notch-1 and ER α transcriptional complexes appears to require DNA, and is likely to be indirect. However, direct contact between Notch-1 and DNA-bound ER α may contribute to complex formation.

The possible physiological role of Notch in ER α signaling deserves further investigation. Under our experimental conditions, Notch-1 knockdown inhibits c-Myc basal expression in the presence, but not absence, of E₂, whereas for pS2 and cyclin-D1, Notch-1 is required for expression in the presence or absence of E₂ (Supplementary Figure 8). Knockdown of either Notch-1 or IKK α prevents transactivation of cyclin-D1 and pS2 by E₂ (Supplementary Figure 9). This suggests that Notch-1 may be a physiological cofactor of E₂ for some ER α -target genes, whereas for other genes Notch-1 may be sufficient to activate ER α -mediated transcription even in the absence of E₂. The latter phenomenon may be pathogenetically important in endocrine-resistant breast cancers. Physiologically, this effect may contribute to luminal differentiation during mammary gland development, as Notch-1 has been shown to play a role in ER α expression during luminal cell fate determination (Dontu *et al.*, 2004; Bouras *et al.*, 2008).

We (Rizzo *et al.*, 2008) have recently shown that in breast cancer cells E₂ inhibits Notch activation and E₂ withdrawal reactivates Notch. This study shows that Notch can activate ER α -dependent transcription, suggesting the existence of a feedback mechanism controlling the Notch–ER α crosstalk.

These findings have significant therapeutic implications. We have shown that anti-estrogens or estrogen withdrawal increases the dependence of breast cancer cells on Notch. Notch-1 knockdown inhibited the growth of MCF-7 cells in charcoal-stripped serum as potently as fulvestrant (Supplementary Figure 10). We have previously shown that NIC induces proliferation in these cells (Rizzo *et al.*, 2008). However, we did not observe accelerated CFSE dilution (a measure of doubling time) in co-culture assays with Jagged-1-expressing fibroblasts (not shown). Thus, it is possible that the main effect of Notch-1 in this setting is to maintain survival, thus allowing proliferation, rather than directly accelerating proliferation.

We confirmed that regulation of E₂-target genes by Notch is not limited to MCF-7 cells, and can be observed in T47D:A18 cells as well (Supplementary Figure 11). Similarly, in T47:A18 xenografts treated with tamoxifen and an oral GSI, pS2 expression was downregulated more effectively than canonical Notch-target genes (Supplementary Figure 12), indicating that inhibition of E₂-target genes may mediate the effects of GSIs in ER α -positive breast cancers and may be an efficacy biomarker. Finally, our study suggests that targeting IKK α , alone or with Notch, may affect the expression of ER α -target genes without further decreasing the expression of canonical Notch-target genes. This may allow us to

circumvent or reduce, thus, the systemic toxicity of Notch inhibitors while selectively affecting breast cancer cells.

Materials and methods

Cell culture

MCF-7 cells from ATCC were grown in RPMI with 10% fetal bovine serum and 6 ng/ml insulin. LTK-PAR and LTK-Jagged-1 cells were generously provided by Dr G Weinmaster (University of California at Los Angeles, Los Angeles, CA, USA) were expanded in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum.

Plasmids and reagents

Notch-1IC (Rizzo *et al.*, 2008) and DN-IKK α (Arsura *et al.*, 2003) constructs have been described. See Supplementary Information for details on additional constructs and reagents.

Western blotting and antibodies

Cell lysis and western blotting were performed as described (Rizzo *et al.*, 2008). Antibodies were as follows: Notch-1 (C-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA), ER α (G-20; Santa Cruz Biotechnology), RBP-Jk (CBF1, D-20; Santa Cruz Biotechnology), MAML1 (AB5975; Chemicon International, Temecula, CA, USA), Notch-1IC (ab8925; Abcam, Cambridge, MA, USA), IKK α (Imgenex, San Diego, CA, USA), p300 (N-15; Santa Cruz Biotechnology), GAPDH (MAB374; Chemicon International), histone deacetylase (H-51; Santa Cruz Biotechnology) and β -actin (Sigma-Aldrich, St Louis, MO, USA).

Real-time RT-PCR

Total RNA was extracted using the RNeasy Mini kit (Qiagen, Valencia, CA, USA); cDNA was produced using the First Strand cDNA synthesis kit (Fermentas, Glen Burnie, MD, USA). Real-time PCR reactions were conducted with an ABI 7300 system using the iTaq SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA, USA). See Supplementary Figure 13 for primers. The RT-PCR internal controls were 18S rRNA for MCF-7 cells grown alone and RPL13a for co-culture experiments where validated human-specific primers were needed to avoid mouse RNA contamination.

Quantitative ChIP

Quantitative ChIP was performed as described (Wu *et al.*, 2005). See Supplementary Information for detailed experimental procedure, and Supplementary Figure 13 for the primers used in real-time PCR. The following antibodies were used: Notch-1 (C-20), RBP-Jk (CBF1, D-20), SRC-1 (M-341) and p300 (N-15) (Santa Cruz Biotechnology); ER α (AB10) (Lab Vision-Neomarkers, Fremont, CA, USA); MAML1 (AB5975) (Chemicon International); IKK α (IMG-136) (Imgenex) and SRC-3 (MA1-845) (Affinity BioReagents, Rockford, IL, USA).

Quantitative *Renilla* IP

Quantitative IP was performed as previously described (Vooijs *et al.*, 2004), with the following antibodies: Notch-1 (C-20), RBP-J κ (CBF1, D-20) (Santa Cruz Biotechnology); ER α (AB10) (Lab Vision-Neomarkers) and MAML1 (AB5975) (Chemicon).

Nuclear extraction and co-IP

Nuclear extraction was performed as described (ElShamy and Livingston, 2004). The following antibodies were used: Notch-1 (C-20), RBP-J κ (CBF1, D-20) and p300 (N-15) (Santa Cruz Biotechnology); MAML1 (AB5975) (Chemicon); IKK α (IMG-136) (Imgenex) and ER α (AB10) (Lab Vision-Neomarkers).

Statistical analysis

For pairwise comparisons, two-tailed unpaired Student's t-tests were used with $\alpha = 0.05$. SigmaStat software (Jandel Scientific, San Jose, CA, USA) was used for statistical analysis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by Grant P01AG025531 (LM, BAO) and the Schmitt Fellowship Foundation (LH). We are grateful to Geraldine Weinmaster, Peter Strack and Rafi Kopan for the gift of reagents and cell lines, and to Sarah Bray for helpful discussions.

References

- Aguilera C, Hoya-Arias R, Haegeman G, Espinosa L, Bigas A. Recruitment of IkappaBalpha to the hes1 promoter is associated with transcriptional repression. *Proc Natl Acad Sci USA*. 2004; 101:16537–16542. [PubMed: 15536134]
- Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, et al. IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. *Mol Biol Cell*. 2003; 14:585–599. [PubMed: 12589056]
- Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, et al. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation. *Oncogene*. 2003; 22:412–425. [PubMed: 12545162]
- Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. *Science*. 1999; 284:770–776. [PubMed: 10221902]
- Baonza A, Freeman M. Control of cell proliferation in the *Drosophila* eye by Notch signaling. *Dev Cell*. 2005; 8:529–539. [PubMed: 15809035]
- Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. *Cell Stem Cell*. 2008; 3:429–441. [PubMed: 18940734]
- Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. *EMBO J*. 1996; 15:2174–2183. [PubMed: 8641283]
- Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. *J Mammary Gland Biol Neoplasia*. 2004; 9:145–163. [PubMed: 15300010]

- Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. *J Mammary Gland Biol Neoplasia*. 2001; 6:23–36. [PubMed: 11467450]
- Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. *J Biol Chem*. 2001; 276:9817–9824. [PubMed: 11139588]
- Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoutte J, et al. Genome-wide analysis of estrogen receptor binding sites. *Nat Genet*. 2006; 38:1289–1297. [PubMed: 17013392]
- Cenni B, Picard D. Ligand-independent activation of steroid receptors: new roles for old players. *Trends Endocrinol Metab*. 1999; 10:41–46. [PubMed: 10322393]
- Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B, Simel EJ, et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. *J Immunol*. 2001; 167:4458–4467. [PubMed: 11591772]
- Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. *Mod Pathol*. 2007; 20:685–693. [PubMed: 17507991]
- Dontu G, Jackson KW, McNicholas E, Kawamura M, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. *Breast Cancer Res*. 2004; 6:605–615.
- Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. *Oncogene*. 1992; 7:1587–1594. [PubMed: 1630819]
- Eeckhoutte J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. *Genes Dev*. 2006; 20:2513–2526. [PubMed: 16980581]
- ElShamy WM, Livingston DM. Identification of BRCA1-IRIS, a BRCA1 locus product. *Nat Cell Biol*. 2004; 6:954–967. [PubMed: 15448696]
- Fernandez-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytes A, et al. Nuclear IKK activity leads to dysregulated Notch-dependent gene expression in colorectal cancer. *Proc Natl Acad Sci USA*. 2007; 104:276–281. [PubMed: 17190815]
- Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). *Oncogene*. 1997; 14:1883–1890. [PubMed: 9150355]
- Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. *Cancer Res*. 1996; 56:1775–1785. [PubMed: 8620493]
- Gillesby BE, Stanostefano M, Porter W, Safe S, Wu ZF, Zacharewski TR. Identification of a motif within the 5' regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. *Biochemistry*. 1997; 36:6080–6089. [PubMed: 9166778]
- Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. *Nat Rev Cancer*. 2007; 7:713–722. [PubMed: 17721435]
- Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. *Dev Cell*. 2005; 9:617–628. [PubMed: 16256737]
- Hayward P, Brennan K, Sanders P, Balayo T, DasGupta R, Perrimon N, et al. Notch modulates Wnt signalling by associating with Armadillo/beta-catenin and regulating its transcriptional activity. *Development*. 2005; 132:1819–1830. [PubMed: 15772135]
- Iso T, Sartorelli V, Poizat C, Iezzi S, Wu HY, Chung G, et al. HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. *Mol Cell Biol*. 2001; 21:6080–6089. [PubMed: 11486045]
- Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. *J Biol Chem*. 2001; 276:13615–13621. [PubMed: 11278408]
- Jehn BM, Bielke W, Pear WS, Osborne BA. Cutting edge: protective effects of notch-1 on TCR-induced apoptosis. *J Immunol*. 1999; 162:635–638. [PubMed: 9916679]
- Jeltsch JM, Roberts M, Schatz C, Garnier JM, Brown AM, Chambon P. Structure of the human oestrogen-responsive gene pS2. *Nucleic Acids Res*. 1987; 15:1401–1414. [PubMed: 3822834]

- Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science*. 1995; 270:1491–1494. [PubMed: 7491495]
- Kiaris H, Politi K, Grimm LM, Szabolcs M, Fisher P, Efstratiadis A, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. *Am J Pathol*. 2004; 165:695–705. [PubMed: 15277242]
- Klinikakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. *Proc Natl Acad Sci USA*. 2006; 103:9262–9267. [PubMed: 16751266]
- Laganier J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. *Proc Natl Acad Sci USA*. 2005; 102:11651–11656. [PubMed: 16087863]
- Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. *Mol Endocrinol*. 2006; 20:3120–3132. [PubMed: 16945990]
- Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, et al. Whole-genome cartography of estrogen receptor alpha binding sites. *PLoS Genet*. 2007; 3:e87. [PubMed: 17542648]
- Maier MM, Gessler M. Comparative analysis of the human and mouse hey1 promoter: hey genes are new notch target genes [In Process Citation]. *Biochem Biophys Res Commun*. 2000; 275:652–660. [PubMed: 10964718]
- Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, et al. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. *Endocrinology*. 2000; 141:4503–4511. [PubMed: 11108261]
- Miele L. Notch signaling. *Clin Cancer Res*. 2006; 12:1074–1079. [PubMed: 16489059]
- Miele L. Rational targeting of Notch signaling in breast cancer. *Expert Rev Anticancer Ther*. 2008; 8:1197–1202. [PubMed: 18699758]
- Nam Y, Sliz P, Pear WS, Aster JC, Blacklow SC. Cooperative assembly of higher-order Notch complexes functions as a switch to induce transcription. *Proc Natl Acad Sci USA*. 2007; 104:2103–2108. [PubMed: 17284587]
- Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. *Mol Cell Biol*. 1997; 17:5338–5347. [PubMed: 9271411]
- Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. *Oncogene*. 2003; 22:6598–6608. [PubMed: 14528285]
- Nunez AM, Berry M, Imler JL, Chambon P. The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. *EMBO J*. 1989; 8:823–829. [PubMed: 2498085]
- Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB. Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. *Mol Cell*. 2005; 18:71–82. [PubMed: 15808510]
- Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles. *Nat Rev Mol Cell Biol*. 2005; 6:542–554. [PubMed: 15957004]
- Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nat Rev Mol Cell Biol*. 2007; 8:49–62. [PubMed: 17183360]
- Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. *Mol Endocrinol*. 1997; 11:1569–1580. [PubMed: 9328340]
- Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. *EMBO J*. 2001; 20:3427–3436. [PubMed: 11432830]
- Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res*. 2005; 65:8530–8537. [PubMed: 16166334]

- Reedijk M, Pinnaduwege D, Dickson BC, Mulligan AM, Zhang H, Bull SB, et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. *Breast Cancer Res Treat.* 2008; 111:439–448. [PubMed: 17990101]
- Rizzo P, Miao H, D'Souza G, Osipo C, Yun J, Zhao H, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. *Cancer Res.* 2008; 68:5226–5235. [PubMed: 18593923]
- Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). *Mol Cell Biol.* 2001; 21:5925–5934. [PubMed: 11486031]
- Saint Just RM, Hansson ML, Wallberg AE. A proline repeat domain in the Notch co-activator MAML1 is important for the p300-mediated acetylation of MAML1. *Biochem J.* 2007; 404:289–298. [PubMed: 17300219]
- Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, et al. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. *Oncogene.* 2008; 27:366–377. [PubMed: 17637753]
- Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, et al. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. *Oncogene.* 2008; 27:5833–5844. [PubMed: 18560356]
- Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. *Cancer Res.* 2006; 66:1517–1525. [PubMed: 16452208]
- Vooijs M, Schroeter EH, Pan Y, Blandford M, Kopan R. Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization. *J Biol Chem.* 2004; 279:50864–50873. [PubMed: 15448134]
- Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. *Genes Dev.* 2006; 20:2096–2109. [PubMed: 16847353]
- Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. *Mol Cell Biol.* 2003; 23:655–664. [PubMed: 12509463]
- Wu J, Iwata F, Grass JA, Osborne CS, Elnitski L, Fraser P, et al. Molecular determinants of NOTCH4 transcription in vascular endothelium. *Mol Cell Biol.* 2005; 25:1458–1474. [PubMed: 15684396]
- Zwijsen RM, Wientjens E, Klompaker R, van der SJ, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. *Cell.* 1997; 88:405–415. [PubMed: 9039267]






Figure 1. Active Notch-1 facilitates the transcription of ER α -target promoters in the absence of E₂. In all experiments, MCF-7 cells were grown in phenol red-free RPMI containing 10% DCC-fetal bovine serum for 3 days prior to harvest. **(a)** MCF-7 cells were transiently transfected with the active form of Notch-1 (NIC) or pcDNA vector control. The mRNA levels of VEGF α , CD44, c-MYC, CCND1, pS2, HEY1 and β -tubulin were measured by real-time RT-PCR after 48 h after transfection. Values are expressed as relative fold induction by NIC over pcDNA, after internal normalization for 18S rRNA. **(b)** MCF-7 cells were co-cultured

with mouse fibroblasts expressing Jagged-1 (LTK-JAG1) or vector-transfected controls (LTK-PAR) for 12 h prior to harvest. The mRNA levels of VEGF α , CD44, c-MYC, CCND1, pS2, HEY1 and β -tubulin were measured by real-time RT-PCR using validated human-specific primers. Values are expressed as relative fold induction by LTK-JAG1 over LTK-PAR, after internal normalization for RPL13a mRNA. (c-h) The schematics of the indicated promoters and ChIP assays. Charcoal-stripped MCF-7 cells were treated with 5 nM E₂ or ethanol (vehicle) for 1 h (left), or co-cultured with LTK cells for 3 h (right) before formaldehyde fixation. ChIP assays were performed with antibodies to Notch-1 or ER α , followed by real-time PCR analysis of the indicated regions of each promoter (arrows). Values are expressed as relative fold increase of specific antibody pull-down over IgG control, after normalization for internal control RPL13a. tts, transcription start site; **P* < 0.001. ChIP, chromatin immunoprecipitation; ER α , estrogen receptor- α ; LTK-JAG1, mouse LTK fibroblasts expressing Notched ligand Jagged-1; LTK-PAR, control vector transduced parental fibroblast; NIC, active form of Notch-1 (Notch-1IC); RPMI, Rosewell Park Memorial Institute; RT-PCR, reverse transcription-PCR; VEGF, vascular endothelial growth factor.

**Figure 2.**


Notch activation increases ER-dependent transcription. In all experiments, MCF-7 cells were grown in phenol red-free RPMI containing 10% DCC-fetal bovine serum for 3 days prior to harvest. (a–g) pS2 real-time RT-PCR experiments: (a) Untransfected MCF-7 cells were treated with 5 nM of E₂ (4 h), 1 μM fulvestrant (24 h) or the combination before harvest. Data are expressed as relative copy number normalized to internal control (18S rRNA); **P* ≤ 0.001. (b) Twelve hours after serum starvation, MCF-7 cells were transfected with NIC or pcDNA vector control. Cells were treated with 5 nM of E₂ (4 h), 1 μM fulvestrant (24 h) or a combination of both before harvest. Data are expressed as relative fold induction of NIC over pcDNA after normalization to the internal control 18S rRNA; **P* ≤ 0.001. (c) MCF-7 cells were treated with E₂ alone or in combination with fulvestrant as described above, and co-cultured with LTK–JAG1 cells for 12 h. Data are expressed as relative fold induction by LTK–JAG1 over LTK–PAR cells after normalization to internal control RPL13a; **P* ≤ 0.001. (d) Western blot of ERα after the treatments described above. (e) Western blot of MCF-7 cells transfected with Notch-1 siRNA or scrambled control (SCB). (f) MCF-7 cells transfected with Notch-1 siRNA or SCB; **P* ≤ 0.001. (g) MCF-7 cells were treated with increasing concentrations of GSI for 24 h. Data are expressed as relative copy number normalized to internal control (18S rRNA). (h, i) ChIP assay on the pS2 promoter. MCF-7 cells were treated with 5 nM E₂, ethanol control for 1 h or E₂ in combination with 1 μM fulvestrant (24 h) after 3 days of charcoal stripping and co-cultured with LTK–JAG1 cells for 3 h. Data expressed as relative fold increase of specific antibody over IgG control, after normalization to internal control RPL13a. (j) MCF-7 cells were grown in charcoal-stripped

media for 3 days and transfected with ER α siRNA or SCB. The western blot shows efficient downregulation of ER α . Actin was used as a loading control. (k) ChIP assay on the pS2 promoter with cells transfected with siRNA to ER α (as described above), co-cultured with LTK–JAG fibroblasts for 3 h and treated with 5 nM E₂ or ethanol for 1 h. ChIP, chromatin immunoprecipitation; ER α , estrogen receptor- α ; GSI, γ -secretase inhibitor; LTK–JAG1, mouse LTK fibroblasts expressing Notched ligand Jagged-1; LTK–PAR, control vector-transduced parental fibroblast; NIC, active form of Notch-1 (Notch-1IC); RPMI, Rosewell Park Memorial Institute; RT–PCR, reverse transcription–PCR; siRNA, short interfering RNA.

**Figure 3.**

Notch-1 requires IKK α and its kinase activity for the transcriptional activation of ER-dependent genes. In all experiments, MCF-7 cells were grown in charcoal-stripped medium for a total of 3 days. (a) MCF-7 cells were transfected with IKK α siRNA. The expression level of IKK α was measured by western blotting. (b) pS2 real-time RT-PCR was performed with the same cells as in panel a. Data are expressed as relative copy number after normalization to internal control 18 S rRNA. Tubulin was used as negative control; * $P < 0.0001$. (c) MCF-7 cells were co-transfected with IKK α siRNA or scrambled control and the

construct expressing NIC or pcDNA control. Overexpression of NIC and downregulation of IKK α were validated by western blotting, using actin as loading control. **(d)** HEY1 and pS2 real-time RT-PCR were performed with the same cells as in panel **c**; * $P \leq 0.001$. **(e)** MCF-7 cells were co-transfected with DN-IKK α (AA) or the empty vector and NIC or pcDNA control. Overexpression of DN-IKK α (AA) and Notch-1 was validated by western blotting, using actin as loading control. **(f)** HEY1 and pS2 real-time RT-PCR were performed with the same cells as in panel **e**; * $P \leq 0.001$. **(g, h)** MCF-7 cells were transfected with IKK α siRNA **(g)** or DN-IKK α **(h)** and co-cultured with LTK-JAG1 or LTK-PAR fibroblasts for 3 h. ChIP assays were performed with antibodies to Notch-1 or ER α , followed by real-time PCR analysis of the pS2 promoter; * $P \leq 0.001$. **(i)** MCF-7 cells were co-cultured with LTK-JAG1 or LTK-PAR fibroblasts for 3 h and treated with 5 nM E₂ or ethanol control for 1 h prior to harvest. ChIP assay was performed with IKK α antibody followed by real-time PCR for the pS2 promoter; * $P \leq 0.001$. ChIP, chromatin immunoprecipitation; DN-IKK α , the dominant-negative form of IKK α ; ER α , estrogen receptor- α ; GSI, γ -secretase inhibitor; LTK-JAG1, mouse LTK fibroblasts expressing Notched ligand Jagged-1; LTK-PAR, control vector-transduced parental fibroblast; NIC, active form of Notch-1 (Notch-1IC); RT-PCR, reverse transcription-PCR.

**Figure 4.**

SRC-1 or SRC-3 are not required, but CSL and MAML1 are indispensable for the effect of Notch-1 on the pS2 promoter. In all experiments, MCF-7 cells were grown in charcoal-stripped medium for a total of 3 days. SRC-1 (a) and SRC-3 (b) were detected by ChIP on the pS2 promoter. Charcoal-stripped MCF-7 cells were co-cultured with LTK-JAG1 or LTK-PAR fibroblasts for 3 h, and treated with 5 nM E₂ (1 h) or 1 μM 4-hydroxytamoxifen (24 h); * $P \leq 0.001$. (c) MCF-7 cells were transfected with CSL siRNA or scrambled control. CSL knockdown was verified by western blotting. (d, e) HEY1 and pS2 real-time RT-PCR was performed with cells transfected with CSL siRNA and co-cultured with LTK fibroblasts. (f) MCF-7 cells were co-transfected with NIC or pcDNA control and DN-MAML1 or the empty vector MigR. HEY1 and pS2 real-time RT-PCR was performed 48 h after transfection. Data are expressed as relative fold induction by NIC over pcDNA (* $P \leq 0.001$, ** $P \leq 0.005$). (g) MCF-7 cells were transfected with DN-MAML1 or the empty vector MigR under charcoal-stripped conditions and co-cultured with LTK cells for 12 h. pS2 mRNA level was measured by real-time RT-PCR; * $P \leq 0.001$. (h) ChIP-PCR of SRC1, MAML1, CSL on pS2 promoter with MCF-7 cells co-cultured with LTK-JAG1 or LTK-PAR fibroblasts; * $P \leq 0.001$. ChIP, chromatin immunoprecipitation; DN-MAML1, the dominant-negative form of MAML1; GSI, g-secretase inhibitor; LTK-JAG1, mouse LTK


fibroblasts expressing Notched ligand Jagged-1; LTK-PAR, control vector-transduced parental fibroblast; NIC, active form of Notch-1 (Notch-1IC); RT-PCR, reverse transcription-PCR; siRNA, short interfering RNA; SRC, steroid receptor coactivator.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript

**Figure 5.**

The Notch-1 and ER α transcriptional complexes interact in chromatin-enriched nuclear extracts. **(a, b)** Schematics for the constructs of N1-RL **(a)** and ER α -RL **(b)**. **(c)** MCF-7 cells were transfected with N1-RL or the negative controls GAPDH-RL (for cytoplasmic proteins) and Cdc2-RL (for nuclear proteins). Cells were harvested after 3 days E₂ starvation and nuclear extraction was performed. Cytoplasmic or nuclear extracts were immunoprecipitated with ER α , CSL and MAML1 antibodies. **(d)** MCF-7 cells were transfected with ER α -RL or negative controls. Cells were harvested after 3 days E₂ starvation and nuclear extraction was performed. Cytoplasm lysates or nuclear extracts were immunoprecipitated with Notch-1 and CSL antibodies; * $P \leq 0.001$. **(e)** Standard IP-western blot was performed on cytoplasmic or nuclear extracts from MCF-7 cells grown in charcoal-stripped medium for 3 days with antibodies to Notch-1, ER α , and CSL. **(f)** MCF-7 cells were grown in charcoal-stripped medium for a total of 3 days. Cells were transfected with Notch-1 siRNA or scrambled control, and harvested 48 h after transfection. The efficiency of nuclear extraction was verified by western blotting (left). IP-western blot was performed with antibodies to Notch-1, ER α and IKK α . A 10- μ l volume of eluted material from each IP was analysed by western blotting for IKK α or MAML1. ChIP, chromatin immunoprecipitation; ER α , estrogen receptor- α ; ER α -RL, *Renilla* luciferase-tagged ER α ; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; N1-RL, *Renilla* luciferase-tagged Notch-1; siRNA, short interfering RNA.

**Figure 6.**

Notch activation recruits p300 to the pS2 promoter. **(a)** ChIP on the pS2 promoter from MCF-7 cells treated with 5 nM E₂ for 1 h after 3 days charcoal stripping. **(b)** ChIP on the pS2 promoter from MCF-7 cells co-cultured with LTK-JAG1 or LTK-PAR fibroblasts for 3 h after 3 days charcoal stripping. Data in panels **a** and **b** are expressed as relative fold increase of specific antibody over IgG control, after normalization to human-specific internal control RPL13a. **(c)** ChIP on the pS2 promoter from MCF-7 cells grown in charcoal-stripped medium for a total of 3 days, transfected with IKKα siRNA or scrambled control, and co-cultured with LTK-JAG1 or LTK-PAR fibroblasts for 3 h. Data are expressed as relative fold induction by LTK-JAG1 over LTK-PAR after normalization to IgG control and internal control RPL13a. **(d)** Right: Co-IP experiments on MCF-7 cells, charcoal-stripped for 3 days and transfected with IKKα siRNA or scrambled control. Left: IKKα knockdown was confirmed by western blotting. **(e)** Co-IP of ERα and p300 on MCF-7 cells, charcoal-stripped for 3 days and transfected with either wild-type or DN-MAML1, or the empty vector control; **P* ≤ 0.05. ChIP, chromatin immunoprecipitation; DN-MAML1, the dominant-negative form of MAML1; LTK-JAG1, mouse LTK fibroblasts expressing Notched ligand Jagged-1; LTK-PAR, control vector-transduced parental fibroblast; siRNA, short interfering RNA.

